MAS in der pädiatrischen Rheumatologie-Reference-Cited by-同舟云学术

MAS in der pädiatrischen Rheumatologie

Published:2022 Issue: Volume: Page:429-436
ISSN:2625-3461
Container-title:Pädiatrische Rheumatologie
language:
Short-container-title:

Author:

Holzinger Dirk

Publisher

Springer Berlin Heidelberg

Link

https://link.springer.com/content/pdf/10.1007/978-3-662-60410-6_32

Reference46 articles.

1. Behrens EM, Beukelman T, Paessler M, Cron RQ (2007) Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 34(5):1133–1138

2. Benedetti B de, Grom Q, Schneider J, de Min B (2019) Emapalumab, an interferon gamma (IFN-Y)-blocking monoclonal antibody, in patients with macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (SJIA). AnnRheumDis 78:178

3. Benedetti F de, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A (1991) Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 34(9):1158–1163

4. Bennett TD, Fluchel M, Hersh AO, Hayward KN, Hersh AL, Brogan TV, Srivastava R, Stone BL, Korgenski EK, Mundorff MB, Casper TC, Bratton SL (2012) Macrophage activation syndrome in children with systemic lupus erythematosus and children with juvenile idiopathic arthritis. Arthritis Rheum 64(12):4135–4142

5. Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, Brunner HI, Griffin T, Graham TB, Sherry DD, Passo MH, Ramanan AV, Filipovich A, Grom AA (2007) The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 56(3):965–971